Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Address
480 ARSENAL WAY, SUITE 100
WATERTOWN, MA 02472
Founded
2018
Number of Employees
58
Website
http://acrivon.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)